Executing at Exelixis

Deciding to use its limited cash to focus only on its most advanced clinical compound may have been the obvious choice for Exelixis Inc., especially after XL184 produced better-than-expected data in mid-November.

But while last week's headlines may have focused on the company's dramatic restructuring - it will eliminate 65% of its workforce over two years - the ability of Exelixis to become "The XL184 Company" ultimately is going to be all about clinical execution...